CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Breast cancer - managing family history - Management
Magnetic resonance imaging
- Women who are known to have a genetic mutation should be offered annual magnetic resonance imaging (MRI) surveillance if they are:
- BRCA1- and BRCA2-mutation carriers and 30–49 years of age.
- TP53-mutation carriers and 20 years of age or older.
- MRI surveillance should be offered annually to:
- Women 30–39 years of age who have a 10-year risk of breast cancer greater than 8%.
- Women 40–49 years of age who have a 10-year risk greater than 20%, or a 10-year risk greater than 12% where mammography has shown a dense breast pattern.
- Women 30–49 years of age who have not been tested but have a high chance of carrying a BRCA1 or TP53 mutation if they have:
- A 50% risk of carrying one of these mutations in a tested family.
- A 50% risk of carrying a BRCA1 or TP53 mutation in an untested or inconclusively tested family with at least a 60% chance of carrying a BRCA1 or TP53 mutation (that is a 30% risk of carrying one of these mutations).
© NHS Institute for Innovation and Improvement